SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets USFDA’s final nod for Eltrombopag Tablets

16 Jan 2026 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg (USRLD: Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg).

Eltrombopag tablets are indicated for the treatment of thrombocytopenia (low platelet count) in specific blood disorders. Eltrombopag works by stimulating bone marrow cells to produce more platelets, thereby reducing the risk of bleeding. Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad. 

Eltrombopag tablets had annual sales of $1262.5 million in the United States (IQVIA MAT Nov-2025). The group now has 429 approvals and has so far filed 505 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

944.40 5.20 (0.55%)
17-Apr-2026 10:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1685.45
Dr. Reddys Lab 1222.70
Cipla 1235.00
Zydus Lifesciences 944.40
Lupin 2325.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×